Truist Securities Reiterates BioXcel Therapeutics (BTAI) at Buy Ahead of April 5th PDUFA, Analysts Expects Approval and Sees Company Well Prepared for Commercial Launch
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $125.00 price target on BioXcel Therapeutics (NASDAQ: BTAI).The analyst quotes ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
